Oracle surpassed estimates for the quarter, and lifted its guidance for fiscal 2027 revenue. During the quarter, Oracle announced plans to raise $45 billion to $50 billion in the fiscal year to expand ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

The money-burning developers of ChatGPT and ⁠Claude sparked an investment mania, with Big Tech set to spend $650 bln this year on the AI race as lenders pile ‌in. ⁠For now, this vast well of capital ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

The latest price target for Oracle (NYSE:ORCL) was reported by Stifel on March 11, 2026. The analyst firm set a price target for $220.00 expecting ORCL to rise to within 12 months (a possible 35.65% ...

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It ...